创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

ZHU Junliang, DAI Quan, ZHU Ren, LONG Sihui, YU Wenying. Advances in Research on Drugs for Treatment of COVID-19[J]. Progress in Pharmaceutical Sciences, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007
Citation: ZHU Junliang, DAI Quan, ZHU Ren, LONG Sihui, YU Wenying. Advances in Research on Drugs for Treatment of COVID-19[J]. Progress in Pharmaceutical Sciences, 2023, 47(7): 519-531. DOI: 10.20053/j.issn1001-5094.2023.07.007

Advances in Research on Drugs for Treatment of COVID-19

  • The SARS-CoV-2 pandemic has brought tremendous impact on global public health security and economy since its outbreak. At present, the global anti-epidemic efforts have achieved phased results, and the SARS-CoV-2 epidemic no longer constitutes "a Public Health Emergency of International Concern", but this does not mean that the SARS-CoV-2 epidemic has ended. The research and development of COVID-19 therapeutic drugs should not only continue, but also need to be further explored. In this article, the infection mechanism of SARS-CoV-2 has been briefly introduced, and the research progress of COVID-19 therapeutic drugs based on virus and host cell targets has also been reviewed.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return